Daiichi Sankyo Co Ltd (4568.T)
1,714JPY
2:00am EDT
¥34 (+2.02%)
¥1,602
¥1,706
¥1,720
¥1,693
2,146,000
3,123,498
¥2,014
¥1,168
About
Overall
| Beta: | 0.85 |
| Market Cap (Mil.): | ¥1,191,139.00 |
| Shares Outstanding (Mil.): | 709.01 |
| Dividend: | 30.00 |
| Yield (%): | 3.57 |
Financials
| 4568.T | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 17.78 | 32.92 | 33.02 |
| EPS (TTM): | 94.49 | -- | -- |
| ROI: | 5.99 | 19.76 | 19.07 |
| ROE: | 7.86 | 20.57 | 20.00 |
Ranbaxy slumps after Daiichi Sankyo says was misled
MUMBAI - Shares in Ranbaxy Laboratories Ltd fell as much as 10.7 percent on Thursday after majority shareholder Daiichi Sankyo Co said it believed former shareholders of the Indian company hid information regarding U.S. regulatory probes.
UPDATE 1-Ranbaxy slumps after Daiichi Sankyo says was misled
(Adds response from Singh family, details; updates share price)
ArQule, Daiichi's colorectal cancer drug fails trial
- An experimental colorectal cancer drug being developed by ArQule Inc and Japan's Daiichi Sankyo Co Ltd failed to improve patient survival without the cancer worsening, in a mid-stage trial, sending ArQule's shares down 18 percent.
UPDATE 2-ArQule, Daiichi's colorectal cancer drug fails trial
* Drug failed to meet goal of improving survival without the cancer growing
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Datamonitor
|
$175.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Thomson Reuters StreetEvents
|
$75.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

